FMP

FMP

Enter

APLS - Apellis Pharmaceutic...

Financial Summary of Apellis Pharmaceuticals, Inc.(APLS), Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discover

photo-url-https://financialmodelingprep.com/image-stock/APLS.png

Apellis Pharmaceuticals, Inc.

APLS

NASDAQ

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

49.93 USD

1.21 (2.42%)

About

ceo

Dr. Cedric Francois M.D., Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.apellis.com

exchange

NASDAQ

Description

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glome...

CIK

0001492422

ISIN

US03753U1060

CUSIP

03753U106

Address

100 Fifth Avenue

Phone

617 977 5700

Country

US

Employee

702

IPO Date

Nov 9, 2017

Summary

CIK

0001492422

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

03753U106

ISIN

US03753U1060

Country

US

Price

49.93

Beta

0.89

Volume Avg.

1.33M

Market Cap

6.02B

Shares

-

52-Week

19.83-94.75

DCF

-33.88

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-11.22

P/B

-

Website

https://www.apellis.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest APLS News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep